AXSM Stock Has Slumped Nearly 20% Over The Past Month, But BofA Sees Selloff As Overdone
Axsome Therapeutics Could Achieve Earnings in 2027 Amid Growing Auvelity Revenue, RBC Says
Morgan Stanley Maintains Equal-Weight on Axsome Therapeutics, Raises Price Target to $249
RBC Capital Maintains Outperform on Axsome Therapeutics, Lowers Price Target to $273
Loading...